DoMore Diagnostics and Paige enters commercial partnership and make Histotype Px® Colorectal available on Paige’s AppLab™ Marketplace

 
 

OSLO – February 8, 2024 – Histotype Px® Colorectal will be added to Paige’s new AppLab™ Marketplace. Together, Paige and DoMore Diagnostics will continue to push the boundaries in digital pathology and make personalized cancer treatment available to patients worldwide.

“We are excited to be part of Paige’s AppLab which ensures seamless and easy integration of AI solutions for end users. This is critical to bring innovation in the field forward,” said Torbjørn Furuseth, Co-Founder and CEO of DoMore Diagnostics. “Paige will be a key partner as we continue on our mission to personalize cancer treatment for patients worldwide with our Histotype Px digital biomarkers.”

Full PR can be found here.

About DoMore Diagnostics

DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.

About Histotype Px® Colorectal

Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, identifying patients who may or may not benefit from adjuvant chemotherapy. Data previously published in The Lancet and Lancet Oncology showed the test can accurately predict survival outcomes in colorectal cancer patients. The Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.

For more information, please visit:

www.domorediagnostics.com.

LinkedIn: https://no.linkedin.com/company/domore-diagnostics

Lancet Oncology: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00391-6/fulltext

Contact:

CEO and Co-Founder Torbjørn Furuseth, MD

tf@domorediagnostics.com

Previous
Previous

DoMore Diagnostics secures EIC Accelerator grant - awarded up to €10 million financing

Next
Next

NOK 16 million public grant awarded by the Research Council of Norway to DoMore Diagnostics